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Abstract
Background
In 2014, the Centers for Medicare and Medicaid Services (CMS) began covering a multitar-
get stool DNA (mtSDNA) test for colorectal cancer (CRC) screening of Medicare beneficia-
ries. In this study, we evaluated whether mtSDNA testing is a cost-effective alternative to
other CRC screening strategies reimbursed by CMS, and if not, under what conditions it
could be.
Methods
We use three independently-developed microsimulation models to simulate a cohort of pre-
viously unscreened US 65-year-olds who are screened with triennial mtSDNA testing, or
one of six other reimbursed screening strategies. Main outcome measures are discounted
life-years gained (LYG) and lifetime costs (CMS perspective), threshold reimbursement
rates, and threshold adherence rates. Outcomes are expressed as the median and range
across models.
Results
Compared to no screening, triennial mtSDNA screening resulted in 82 (range: 79–88) LYG
per 1,000 simulated individuals. This was more than for five-yearly sigmoidoscopy (80
(range: 71–89) LYG), but fewer than for every other simulated strategy. At its 2017 reim-
bursement rate of $512, mtSDNA was the most costly strategy, and even if adherence were
30% higher than with other strategies, it would not be a cost-effective alternative. At a
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substantially reduced reimbursement rate ($6–18), two models found that triennial mtSDNA
testing was an efficient and potentially cost-effective screening option.
Conclusions
Compared to no screening, triennial mtSDNA screening reduces CRC incidence and mortal-
ity at acceptable costs. However, compared to nearly all other CRC screening strategies
reimbursed by CMS it is less effective and considerably more costly, making it an inefficient
screening option.
Introduction
Colorectal cancer (CRC) is the second most common cause of cancer death in the United
States [1]. Randomized trials of fecal occult blood tests (FOBTs) and flexible sigmoidoscopy
have shown that screening can effectively reduce both CRC incidence [2–6] and mortality [2–
12]. In June 2016, the US Preventive Services Task Force updated their CRC screening recom-
mendations, including guidelines on the use of FOBTs, flexible sigmoidoscopy, colonoscopy,
and the recently-developed multitarget stool DNA test (mtSDNA) [13].
In April 2014, Imperiale et al. [14] published the findings of a study evaluating the test per-
formance of the mtSDNA test, Cologuard (Exact Sciences Corporation), based on a single
round of screening. Cologuard combines DNA assays for multiple aberrant gene mutations
and a proprietary fecal immunochemical assay. Compared with a fecal immunochemical test
(FIT), Cologuard demonstrated higher sensitivity for CRC and advanced adenomas but lower
specificity. In October 2014, the Centers for Medicare and Medicaid Services (CMS) granted
coverage of Cologuard once every 3 years (the interval recommended by the manufacturer) for
asymptomatic, average-risk Medicare beneficiaries [15]. Following CMS’s Clinical Laboratory
Fee Schedule (CLFS), reimbursement for Cologuard was set by “crosswalking” to comparable
diagnostic tests already on the CLFS. This process yielded a 2014 reimbursement rate for Colo-
guard of $492.72 per test [16].
CMS requested an analysis of mtSDNA screening of Medicare enrollees from the MITRE
Corporation. MITRE commissioned investigators from the Cancer Intervention and Surveil-
lance Modeling Network (CISNET) to assess whether mtSDNA testing is a cost-effective alter-
native to other CRC screening strategies available to Medicare beneficiaries, and if not, to
assess at what reimbursement rate, level of screening uptake, or screening interval it could be a
cost-effective option.
Methods
CISNET models
We used three independently-developed microsimulation models of CRC from the National
Cancer Institute’s CISNET consortium—the CRC Simulated Population Model for Incidence
and Natural History (CRC-SPIN), Microsimulation Screening Analysis for CRC (MISCAN),
and Simulation Model of CRC (SimCRC)—to evaluate the cost-effectiveness of screening
Medicare beneficiaries with the mtSDNA test, or with an alternative CRC screening approach.
All models describe the natural history of CRC in an unscreened population, based on the ade-
noma-carcinoma sequence [17–19]. Simulated persons enter free of colonic and rectal lesions
at age 20. As they age, they are at risk of developing adenomas. Each adenoma may grow in
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size, and some may transition to a preclinical (i.e., undiagnosed) CRC. Preclinical cancers may
become symptomatic, at which point the person becomes a clinically-detected case. Persons
may die from causes other than CRC at any age, and persons with detected CRC may die from
the disease.
Each model has a screening component that allows the natural history of CRC to be inter-
rupted due to the detection of a preclinical cancer or the detection and removal of adenoma
(s). The chance that screening detects asymptomatic disease in a simulated person depends on
the sensitivity of the screening test and, for endoscopic tests, whether the lesion is within the
reach of the scope. Screened persons without an underlying lesion may have a false-positive
test result and undergo an unnecessary follow-up colonoscopy. Non-adenomatous polyps
(e.g., hyperplastic polyps) are not modeled explicitly, but their detection is reflected in the
false-positive rates of the tests. The impact of screening depends on the characteristics of the
test performed, and on how frequently it is repeated.
CRC screening
We used the models to simulate cohorts of previously unscreened US 65-year-olds, with
mtSDNA every 3 years (as specified in the final coverage determination) and six other strate-
gies available to Medicare beneficiaries [20]: annual fecal occult blood testing (FOBT) with
either a high-sensitivity guaiac-based FOBT (gFOBT) or a FIT, 5-yearly flexible sigmoidos-
copy, 10-yearly flexible sigmoidoscopy with annual gFOBT or annual FIT, and 10-yearly colo-
noscopy. We assumed all screening begins at age 65 and ends no later than age 75. Individuals
with a positive non-colonoscopy screening test undergo a follow-up colonoscopy. Individuals
with adenomas detected at a screening or follow-up colonoscopy transition to a surveillance
regimen [21], with colonoscopy performed every 3 or 5 years (dependent on findings) until at
least age 85.
For the base-case analysis, we assumed 100% adherence to all screening, follow-up, and sur-
veillance procedures to assess the effect of screening in those willing to be screened. Alternative
assumptions were explored in sensitivity analyses.
Assumptions about test accuracy were based on published findings (Table 1). Complication
risks from colonoscopy were obtained from a study by Van Hees et al. [22] that estimated
excess risks of serious gastrointestinal events, other gastrointestinal events, and cardiovascular
events by age and polypectomy status among Medicare beneficiaries undergoing colonoscopy
compared with a matched control group that did not have colonoscopy [23].
Costs
The analysis was conducted from the CMS perspective, and as such, costs were valued by
Medicare reimbursement rates and excluded beneficiary copayments and cost-sharing pay-
ments. Costs of stool-based screening tests were based on the 2017 Clinical Diagnostic Labora-
tory Fee Schedule and costs of endoscopic tests were based on 2014 average Medicare
payments (Table 2). For a detailed description of the derivation of these costs, see S1 Appendix.
Endoscopy payments were updated to 2017 dollars using the Personal Health Care Deflator
Price Index [34]. For each type of colonoscopy complication, the average payment by CMS
was calculated using frequency data on hospitalizations for colonoscopy complications (per-
sonal communication, Craig Parzynski, MS, of Yale University).
Net costs of CRC-related care by stage at diagnosis and phase of care were obtained from
an updated analysis of 2007–2013 SEER-Medicare linked data ([35] and personal communica-
tion, Angela Mariotto, PhD) and were updated to 2017 dollars (Table 2).
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Table 1. Test characteristics� used in the analysis.
Sensitivity Analysis
Screening Test
Test Characteristic
Base-Case Value, % Source Worst-Case
Value, %
Best-Case
Value, %
Source
mtSDNA Imperiale et al,
2014[14]
Imperiale et al, 2014[14]
Specificity† 89.8 Not varied Not varied Not varied
Sensitivity for adenomas <10 mm
17.2‡ 15.9‡ 18.6‡
Sensitivity for adenomas�10 mm
42.4§ 38.7§ 46.2§
Sensitivity for colorectal cancer 92.3 84 97
FIT (cutoff 20 μg of hemoglobin per g of feces) Imperiale et al,
2014[14]
Imperiale et al, 2014[14]
Specificity† 96.4 Not varied Not varied Not varied
Sensitivity for
adenomas <10 mm
7.6‡ 6.7‡ 8.6‡
Sensitivity for
adenomas�10 mm
23.8§ 20.8§ 27§
Sensitivity for colorectal cancer 73.8 62.3 83.3
gFOBT Zauber et al, 2008
[24]
Specificity† 92.5 Not varied Not varied Not varied
Sensitivity for adenomas <6 mm 7.5k 7.5k 7.5k Zauber et al, 2008[24]
Sensitivity for
adenomas 6–9 mm
12.4 10 26.2 Zauber et al, 2008[24]
Sensitivity for
adenomas�10 mm
23.9 17.7 49.4 Zauber et al, 2008[24]
Sensitivity for colorectal cancer 70 61.5 79.4 Levi et al, 2011[25] Allison
et al, 1996[26]
Colonoscopy (within reach)¶
Specificity† 86�� Schroy et al, 2013
[27]
Not varied Not varied Not varied
Sensitivity for adenomas <6 mm 75 van Rijn et al,
2006[28]
70 79 Zauber et al, 2008[29]
Sensitivity for adenomas
6–9 mm
85 van Rijn et al,
2006[28]
80 92 Zauber et al, 2008[29]
Sensitivity for
adenomas�10 mm
95 van Rijn et al,
2006[28]
93.1 99.5 Johnson et al, 2008[30]
Sensitivity for colorectal cancer 95 By assumption 93.1 99.5 By assumption
Reach†† 95 to end of cecum, remainder between
rectum and cecum
By assumption Not varied Not varied
Sigmoidoscopy (within reach)
Specificity† 87�� Weissfeld et al,
2005[31]
Not varied Not varied
Sensitivity for adenomas <6 mm 75 By assumption 70 79
Sensitivity for
adenomas 6–9 mm
85 By assumption 80 92
Sensitivity for
adenomas�10 mm
95 By assumption 93.1 99.5
Sensitivity for colorectal cancer 95 By assumption 93.1 99.5
(Continued)
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Cost-effectiveness analysis
We used the simulation models to calculate lifetime costs of CRC screening and related care
and life expectancy for a previously unscreened cohort of 65-year-old Medicare beneficiaries
under eight CRC screening strategies, including no screening. We conducted an incremental
cost-effectiveness analysis from the perspective of CMS and discounted both future costs and
life-years 3% annually to account for time preference for present over future outcomes [36].
Screening strategies were ranked by increasing costs. Strategies that were more costly and less
effective than another strategy (i.e., strongly dominated strategies) were eliminated from con-
sideration because they were inefficient screening options. Of the remaining strategies, those
that were less costly and less effective than another but provided an additional life-year gained
(LYG) at a higher incremental cost (i.e., weakly dominated strategies) were also eliminated
from consideration. The relative performance of the remaining non-dominated strategies was
measured using the incremental cost-effectiveness ratio (ICER), defined as the additional cost
of a specific strategy, divided by its additional clinical benefit (in this case, LYG), compared
with the non-dominated strategy with costs closest to, but lower than, the strategy of interest.
All non-dominated strategies represent the set of potentially cost-effective options and
together comprise the efficient frontier. Which strategy is ultimately deemed to be cost effec-
tive depends on the willingness to pay for a LYG. Although there is no official willingness-to-
pay (WTP) threshold in the US, a strategy with an ICER less than $50,000–100,000 per LYG is
generally considered to provide good value [37]. In this analysis, we assumed a WTP threshold
of $100,000 per LYG.
Table 1. (Continued)
Sensitivity Analysis
Screening Test
Test Characteristic
Base-Case Value, % Source Worst-Case
Value, %
Best-Case
Value, %
Source
Reach 76–88 to sigmoid-descending junction; 0
beyond the splenic flexure
Atkin et al, 2002
[32]
Painter et al, 1999
[33]
Not varied Not varied
FIT = fecal immunochemical test; gFOBT = sensitive guaiac-based fecal occult blood test; mtSDNA = multitarget stool DNA test.
� Sensitivity estimates are per person for stool-based tests and per-lesion for endoscopic tests. Specificity is defined as the probability of a negative test result among
persons who do not have adenomas or colorectal cancer.
† Specificity is defined as the probability of a negative test result among persons who do not have adenomas or colorectal cancer.
‡ Sensitivity for persons with non-advanced adenomas. For persons with <6 mm adenomas, we assume that the sensitivity of the test is equal to the positivity rate in
persons without adenomas (i.e., 1 –specificity). The sensitivity for persons with 6–9 mm adenomas is chosen such that the weighted average sensitivity for persons with
<6 mm and with 6–9 mm adenoma(s) is equal to that of non-advanced adenomas.
§ Sensitivity for persons with advanced adenomas (i.e., adenomas�10 mm and/or adenomas with advanced histology). Sensitivity was not reported for the subset of
�10 mm adenomas.
kWe assume that <6 mm adenomas do not bleed, and therefore cannot cause a positive stool test. We also assume that gFOBT can be positive due to bleeding from
other causes, the probability of which is equal to positivity rate in persons without adenomas (i.e., 1–0.925).
¶ We assume the same test characteristics for screening colonoscopies as for colonoscopies for diagnostic follow-up or for surveillance. We assume no correlation in
findings between sigmoidoscopy and subsequent diagnostic colonoscopy.
�� The lack of specificity with endoscopy reflects the detection of non-adenomatous polyps, which, in the case of sigmoidoscopy, may lead to unnecessary diagnostic
colonoscopy, and in the case of colonoscopy screening, leads to unnecessary polypectomy, which is associated with an increased risk complications.
†† We assume that 5% of persons undergoing colonoscopy require 2 procedures to achieve complete visualization and that the cecum is ultimately visualized in 95% of
patients.
https://doi.org/10.1371/journal.pone.0220234.t001
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Outcomes
Outcomes are reported as the results predicted by each of the three models, focusing on the
median prediction, along with estimates from the other two models, which define the range
across models.
Sensitivity analyses
Although this analysis was primarily performed to inform reimbursement decisions for Medi-
care beneficiaries, we included a sensitivity analysis in which we simulated a 50-year-old
cohort.
We also explored the cost-effectiveness of mtSDNA testing using quality-adjusted life years
(QALYs) gained as the measure of effectiveness. The assumptions for utilities are provided in
S3 Table.
Table 2. Reimbursement for screening tests and for colonoscopy complications, and annual reimbursements for cancer care used in the analysis.
Description Reimbursement� ($)
Screening tests
mtSDNA 512
FIT 22
gFOBT 4
Colonoscopy, without polypectomy, by indication
- Screening 735
- Diagnostic 639
- Surveillance 724
Colonoscopy, with polypectomy 870
Sigmoidoscopy 337
Colonoscopy complications
Serious GI complication (perforations, GI bleeding, transfusions) 6,847
Other GI complication (paralytic ileus, nausea and vomiting, dehydration, abdominal pain) 4,878
Cardiovascular complication (myocardial infarction or angina, arrhythmias, congestive heart failure, cardiac or respiratory
arrest, syncope, hypotension, or shock)
5,347
Cancer care
Annual reimbursement by stage at diagnosis ($)
Phase of care† I II III IV
Initial phase 33,341 47,283 67,300 97,931
Continuing phase 2,685 3,266 5,258 26,474
Terminal phase, non-CRC death 16,701 17,963 24,990 61,238
Terminal phase, CRC death 68,339 77,098 79,770 99,255
CRC = colorectal cancer; FIT = fecal immunochemical test; gFOBT = sensitive guaiac-based fecal occult blood test; GI = gastrointestinal; mtSDNA = multitarget stool
DNA test.
� All costs are expressed in 2017 US dollars. Costs of stool-based tests are based on the 2017 Centers for Medicare and Medicaid Services Clinical Laboratory Fee
Schedule. Costs of endoscopic procedures are based on 2014 average Medicare payments for a screening sigmoidoscopy and for each type of colonoscopy and include
payments for pathology and anesthesia services.
† The initial phase of care is the first 12 months after diagnosis, the last year of life phase is the final 12 months of life, and the continuing phase is all the months between
the initial and last year of life phases.
https://doi.org/10.1371/journal.pone.0220234.t002
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Threshold analyses
If the triennial mtSDNA test strategy was found to be dominated by other screening options,
we calculated the maximum cost per mtSDNA test (i.e., the threshold cost) for that strategy to
be on the efficient frontier (i.e., to be potentially cost effective). If the mtSDNA test strategy
was the least effective strategy, we calculated the threshold cost at which its total discounted
cost would be $1 less than the total cost of the least expensive strategy on the efficient frontier
(prior to the addition of the mtSDNA test strategy). If the mtSDNA test strategy was the most
effective strategy, we calculated the threshold cost at which its ICER was<$100,000 per LYG.
If the mtSDNA test strategy was between the least and most effective strategies on the efficient
frontier, we calculated the threshold cost at which its ICER was equal to the ICER of the effi-
cient strategy with LYG closest to and higher than the LYG of the mtSDNA test strategy.
Since the availability of the mtSDNA test could entice a previously unscreened individual to
undergo screening, we also identified the threshold mtSDNA test cost for scenarios in which
the adherence of the mtSDNA strategy was greater than that of all other screening strategies.
For this sensitivity analysis we assumed a fixed overall adherence for each test [38], where
those that adhere are completely adherent to screening and those who do not are completely
non-adherent. We then increased the relative adherence for the mtSDNA test strategy from 0
to 40% higher than with other tests and calculated the associated threshold mtSDNA test costs.
Note that simulating adherence in this manner means that the threshold costs do not change
with the overall level of adherence of all other screening strategies, only with the relative
increase in adherence with mtSDNA testing.
Threshold costs for mtSDNA were also identified in sensitivity analyses with: higher and
lower estimates of the sensitivity of either mtSDNA testing or of all other screening modalities
(Table 1); and annual and biennial screening intervals for mtSDNA testing.
Threshold costs are only influenced by the WTP threshold if mtSDNA testing is the most
effective strategy. For those threshold analyses, we also present the threshold cost for WTP
thresholds of $50,000 and $150,000 per LYG.
Results
In the absence of screening, 64 (range across models: 61–64) per 1,000 65-year-olds will be
diagnosed with CRC in their lifetimes (Table 3), resulting in approximately $4.0 million
(range: $3.9–4.1 million) in discounted lifetime direct medical costs. All screening strategies
yielded large reductions in CRC incidence and mortality. Assuming 100% adherence, the
reduction in lifetime risk of CRC with one of the established screening strategies ranged from
50% (range: 36–59%) with annual FIT screening to 73% (range: 58–86%) with 10-yearly colo-
noscopy screening (S1 Fig, Panel A). With 46% (range: 33–54%) CRC risk reduction, triennial
mtSDNA testing was less effective. Reductions in lifetime risk of CRC death (S1 Fig, Panel B)
were higher than reductions in incidence but followed a similar pattern. The reduction in life-
time risk of CRC death ranged from 66% (range: 62–68%) with triennial mtSDNA testing to
84% (range: 80–92%) with 10-yearly colonoscopy screening.
Cost-effectiveness analysis
Two screening strategies were found to be efficient by all models: 10-yearly colonoscopy and
annual FOBT using either gFOBT or FIT (Fig 1, Table 3). Ten-yearly sigmoidoscopy combined
with annual gFOBT was also an efficient screening option in two models (MISCAN and
SimCRC).
In one model (MISCAN), triennial mtSDNA testing yielded the fewest LYG of all evaluated
strategies, and in the other two models it had the second-fewest LYG after 5-yearly
Cost-effectiveness of multitarget stool DNA testing
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sigmoidoscopy. Two models (MISCAN and SimCRC) found that triennial mtSDNA testing
was the most expensive strategy evaluated; one model (CRC-SPIN) found that only no screen-
ing was more expensive than mtSDNA testing. Given the limited LYG and higher costs, trien-
nial mtSDNA testing was not an efficient alternative to other strategies reimbursed by CMS.
Sensitivity analyses
Simulating a 50-year-old cohort or using QALYs as the measure of effectiveness did not
change the conclusions about the comparative effectiveness and cost-effectiveness of the differ-
ent strategies (S4 and S5 Tables, respectively). Triennial mtSDNA testing yielded either the
fewest (MISCAN) or second-fewest (CRC-SPIN and SimCRC) LYG; and in two models (MIS-
CAN, SimCRC) mtSDNA testing was the most expensive strategy, while in one (CRC-SPIN)
only no screening was more costly.
Threshold analyses
In threshold analyses, two models (MISCAN and SimCRC) found that the reimbursement for
the mtSDNA test must be considerably lower, in the range of $6–18 per test, for triennial
mtSDNA screening to be an efficient and potentially cost-effective strategy (Fig 2). In one
model (CRC-SPIN), there was no level of reimbursement at which triennial mtSDNA testing
would be cost effective compared with currently recommended screening options (i.e., the
threshold cost was negative), due to the benefit being low relative to other tests.
If the triennial mtSDNA test strategy would motivate individuals who would not otherwise
be screened to participate in screening, then the threshold cost at which the mtSDNA strategy
would be on the efficient frontier would increase. Adherence with mtSDNA testing would
need to be 31–53% better than with other tests in order for triennial mtSDNA testing to be effi-
cient at the base-case reimbursement rate of $512 (Fig 2, Panel A).
Table 3. Undiscounted colorectal cancer cases and deaths, and discounted costs and life-years gained with associated incremental cost-effectiveness ratio of no colo-
rectal cancer screening and seven colorectal cancer screening strategies in a cohort of 1,000 previously unscreened 65-year-olds, by model.
Strategy CRC-SPIN MISCAN SimCRC
CRC
cases
CRC
deaths
Lifetime
costs,�
million $
LYG� ICER,
$
CRC
cases
CRC
deaths
Lifetime
costs,�
million $
LYG� ICER,
$
CRC
cases
CRC
deaths
Lifetime
costs,�
million $
LYG� ICER,
$
No screening 64 23 3.928 0 D 61 25 3.966 0 D 64 25 4.086 0 D
gFOBT 1y 25 6 2.387 89.5 - - 39 8 3.599 86.6 D 31 7 3.134 91.6 D
FIT 1y 27 6 2.485 88.3 D 39 8 3.561 87.2 - - 32 7 3.131 91.9 - -
SIG 5y 29 9 3.110 70.8 D 30 7 3.878 88.9 D 28 9 3.603 80.1 D
SIG 10y
+ gFOBT 1y
17 4 2.489 99.0 D 29 6 3.747 98.7 16,200 23 5 3.282 99.1 20,900
SIG 10y
+ FIT 1y
17 4 2.581 98.5 D 29 6 3.782 99.0 D† 23 5 3.320 99.3 D†
COL 10y 9 2 2.479 107.4 5,100 25 5 3.846 101.6 34,700 17 4 3.406 102.8 33,200
mtSDNA 3y 30 8 3.887 79.3 D 41 9 4.889 81.7 D 34 8 4.512 87.9 D
- - = default strategy (i.e., the least costly and least effective non-dominated strategy); COL = colonoscopy; CRC = colorectal cancer; D = dominated; FIT = fecal
immunochemical test; gFOBT = high sensitivity guaiac-based fecal occult blood test; ICER = incremental cost-effectiveness ratio; LYG = life-years gained compared
with no screening; mtSDNA = multitarget stool DNA test; SIG = flexible sigmoidoscopy.
� Future costs and life-years are discounted at a 3% annual rate.
† Indicates a dominated strategy is weakly dominated (i.e., one of the other strategies provides more life-years gained than this strategy, and it has a lower incremental
cost-effectiveness ratio). All other dominated strategies are strongly dominated (i.e., provide fewer life-years gained and have higher total costs than another strategy).
https://doi.org/10.1371/journal.pone.0220234.t003
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Fig 1. Discounted costs and discounted life-years gained per 1,000 persons aged 65 years for eight colorectal
cancer screening strategies and the efficient frontier connecting the economically efficient strategies, for
CRC-SPIN (Panel A), MISCAN (Panel B) and SimCRC (Panel C) models. Discounted costs and life-years gained
reflect total costs and life-years gained of a screening program, accounting for time preference for present over future
outcomes. Life-years gained are plotted on the y-axis, and total costs are plotted on the x-axis. Each possible screening
Cost-effectiveness of multitarget stool DNA testing
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If mtSDNA was assumed to perform better at detecting disease or if other modalities were
assumed to perform worse than assumed in the base-case analysis, estimated reimbursement
rates increased to $32–42 (one model (CRC-SPIN) continued to find no reimbursement rate
at which the mtSDNA test strategy would be an efficient option) and $40 (range: $1–52),
respectively (S2 Fig). When the interval of mtSDNA screening was shortened to 2 years or 1
year, threshold costs increased to $51 (range: $21–52) and $70 (range: $54–75), respectively
(Fig 2, Panel B).
The WTP threshold only influenced the threshold cost of the mtSDNA test when we
assumed that adherence with mtSDNA testing would be higher than with other strategies. For
SimCRC the threshold cost is affected by the WTP threshold at�17% higher adherence, for
MISCAN the threshold cost is affected at�24% higher adherence, and for CRC-SPIN the
threshold cost is affected at�36% higher adherence (S3 Fig).
Discussion
This study showed that, with perfect adherence, a 10-year period of triennial mtSDNA screen-
ing in previously unscreened 65-year-olds was slightly less effective in terms of LYG than a
10-year period of annual FIT screening. At its 2017 reimbursement rate of $512 per test, trien-
nial mtSDNA testing was the most costly strategy and was therefore not cost effective com-
pared to other screening options available to Medicare beneficiaries. Per-test reimbursement
for the mtSDNA test would need to be less than $6–18 (or even negative, according to one
model) for triennial screening to be potentially cost effective compared to other reimbursed
strategies. Higher reimbursement rates could be supported with more frequent screening: $51
(range: $21–52) per test with biennial screening and $70 (range: $54–75) per test with annual
screening.
These results show that if a previously unscreened 65-year-old were to choose between tri-
ennial mtSDNA testing and another reimbursed strategy, it would be both more effective and
more cost effective to choose the other strategy. However, mtSDNA testing does reduce CRC
incidence and mortality compared to no screening at all. Therefore, mtSDNA testing could be
cost effective if it were reserved solely for use by those who are unwilling to participate in CRC
screening with any other available test. However, this test has been marketed to the US public
for general use, and a study on early adoption of mtSDNA testing found higher usage of
mtSDNA among patients with prior CRC screening compared to those without [39].
Despite its higher sensitivity for advanced adenomas and cancer, triennial mtSDNA testing
yielded fewer LYG than the two other stool-based CRC screening strategies evaluated. The
lower effectiveness can be explained by the longer screening interval. For example, consider a
simple case of a person with a single advanced adenoma: if tested with annual FIT, the proba-
bility of a positive test is 0.558 after 3 annual screens [i.e., 1—(1–0.238)3], if screening results
are independent within an individual. If tested with triennial mtSDNA, there would be only
one opportunity for detection in the 3-year period, with a probability of a positive test equal to
strategy is represented by a point. Strategies that form the solid line connecting the points lying left and upward are the
economically rational subset of choices. This line is called the efficient frontier. The inverse slope of the line represents
the incremental cost-effectiveness ratio of the connected strategies. Points lying to the right and beneath the line
represent the dominated strategies. Screening with the multitarget stool DNA test every 3 years has higher costs and
fewer life-years gained than screening annually with either gFOBT or FIT, and the multitarget stool DNA strategy is
therefore strongly dominated. COL = colonoscopy; FIT = fecal immunochemical test; gFOBT = guaiac-based fecal
occult blood test; LYG = life-years gained; mtSDNA = multitarget stool DNA test; SIG = flexible sigmoidoscopy.
https://doi.org/10.1371/journal.pone.0220234.g001
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Fig 2. Sensitivity analyses: Reimbursement thresholds for the mtSDNA test at which the mtSDNA test strategy is efficient compared with other reimbursed
CRC screening strategies for different levels of adherence with the mtSDNA strategy (Panel A) and for different intervals of screening with the mtSDNA test
(Panel B). mtSDNA = multitarget stool DNA test. � For these adherence levels, the threshold cost of mtSDNA test was dependent on the willingness-to-pay threshold.
S3 Fig shows the threshold costs for willingness-to-pay thresholds of $50,000 and $150,000 per life year gained.
https://doi.org/10.1371/journal.pone.0220234.g002
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0.424. In summary, if tests are independent within individuals then a program of annual FIT is
both more sensitive and more specific than triennial mtSDNA. If performed annually or bien-
nially, programmatic sensitivity of mtSDNA screening would increase, but this would likely
come at the cost of increased false-positive test results. Therefore, threshold costs only showed
a modest increase when the interval was shortened.
When reimbursed at $512 per test, mtSDNA could only be cost effective compared to other
strategies if adherence with mtSDNA were considerably higher (31–53% higher) than adher-
ence with other tests. The mtSDNA test may appeal to some unscreened persons because it is
non-invasive, has higher sensitivity (but lower specificity) than other stool tests and can be per-
formed less frequently. However, it is still a stool test (and in fact, requires patients to sample
from the collected stool for the immunochemical assay portion of the test), and, as such, the
demonstrated barriers to this form of screening, such as handling of stool and storing stool in
the house for a short period of time [40] also apply to mtSDNA testing. Furthermore, mtSDNA
does not eliminate the barriers common to all screening tests, namely financial barriers, failure
of clinicians to advise about CRC screening, and not knowing testing was necessary [40].
CMS’s high reimbursement rate for Cologuard—more than 20 times the reimbursement
for other stool-based screening tests for CRC—is the result of federal regulations for setting
reimbursement for new diagnostic laboratory tests. Payment for a new diagnostic laboratory
test is set by one of two approaches: “cross-walking” or “gap-filling” [41]. Cross-walking is
used if the new test is comparable to one or more existing tests already reimbursed under the
Clinical Laboratory Fee Schedule (CLFS); reimbursement for the new test is set equal to the
reimbursement for the comparable test(s). If no comparable test exists, then payment for a
new diagnostic laboratory test is set using the gap-filling approach. With that approach, other
information is taken into consideration, including information on reimbursement for the test
in non-Medicare settings and resource use required for other relevant tests. Reimbursement
for Cologuard was set by cross-walking to three existing codes on the CLFS (81315, 81275, and
82274), yielding the 2014 reimbursement of $492.72 [42]. Had CMS instead used the gap-fill-
ing approach, it is possible that CRC screening with Cologuard would have been a cost-effec-
tive alternative to other tests reimbursed by CMS. Reimbursement for clinical laboratory tests,
including gFOBT, FIT, and Cologuard, changed when Section 216 of the Protecting Access to
Medicare Act of 2014 went into effect on January 1, 2018 [43]. In 2019, the reimbursement for
gFOBT, FIT, and Cologuard were $4.38, $17.67, and $508.87, respectively.
Our findings are in line with our previous analysis of the cost-effectiveness of stool DNA
testing, in which we considered a hypothetical test called “sDNA version 2.0” [44, 45]. This test
had sensitivity and specificity similar to the mtSDNA test, but was never available to the public.
For that test, we found threshold reimbursement rates of $17–41, which are similar to the cur-
rent estimates.
A recent modeling study by Ladabaum and Mannalithara [46] also showed that mtSDNA
testing is not cost effective compared to other screening modalities, unless mtSDNA screening
resulted in higher participation rates or would cost less than its current reimbursement rate.
Our study incorporates three models that all consistently show that adding mtSDNA screening
to the menu of CRC screening options results in even lower value than estimated by Ladabaum
and Mannalithara. We found that mtSDNA screening is not cost effective even under
extremely unrealistic assumptions of a 30% higher adherence than with other tests or test costs
of $70. The most likely reason for the difference in threshold costs and adherence, is that Lada-
baum and Mannalithara performed their threshold analysis for very specific situations, with
either $153 for patient navigation costs added to the cost of FIT, or assuming that only 45% of
individuals would ever participate in FIT-based screening.
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An important strength of the current study is the use of three independently developed
models. Some limitations are noteworthy. First, the models assume that all CRCs arise through
the traditional adenoma–carcinoma sequence, and none incorporate a separate pathway for
sessile serrated adenomas. However, for both FIT and mtSDNA, the sensitivity for detecting
advanced adenomas includes both traditional advanced and sessile serrated adenomas [14].
Our models would underestimate the effectiveness of mtSDNA compared to FIT only if
mtSDNA plus diagnostic colonoscopy would detect more serrated adenomas than FIT plus
diagnostic colonoscopy and these lesions have higher malignant potential than traditional
advanced adenomas. There is evidence to suggest that FIT might be less sensitive than
mtSDNA for sessile serrated adenomas [14, 47], but their malignant potential seems compara-
ble to that of traditional advanced adenomas [48]. Therefore, the impact on (cost-)effectiveness
outcomes of not having two separate pathways to CRC in our models is expected to be limited.
Second, the models simulate the progression from adenoma to CRC by allowing adenomas
to increase in size over time. Because adenoma size and presence of villous components or
high-grade dysplasia are highly correlated [49], size indirectly represents histology and grade.
However, none of the models separately simulate the step from adenoma with low-grade dys-
plasia to adenoma with high-grade dysplasia. For the sensitivity of mtSDNA to detect large
adenomas (�1 cm), we used the estimate for advanced adenomas from Imperiale et al. [14],
who defined advanced adenomas as those with high-grade dysplasia or�25% villous histologic
features or measuring�1 cm in size. As colonoscopy sensitivity increases with size, but not
histology, of the adenoma, the follow-up colonoscopy after a positive mtSDNA test will detect
more high-grade dysplasia and adenomas with villous components if they are all assumed to
be of large size, as opposed to if we had modeled histology and grade explicitly. As a result, we
may have overestimated the effectiveness of mtSDNA testing.
Third, the simulated cohort did not have any CRC screening prior to age 65. In practice,
the Medicare population increasingly consists of individuals who have already had some type
of CRC screening. Although the value of screening is lower for individuals with prior screening
(because they have lower disease prevalence), the relative difference in effectiveness and cost-
effectiveness between different screening strategies is expected to be similar.
Fourth, we assumed conditional independence of repeat screenings. Consequently we
assumed that there were no systematic false-negative results for adenomas and cancers. This
assumption may not hold for gFOBT and FIT testing because bleeding of a lesion may not be a
random event [50]. However, this assumption may not hold for mtSDNA testing either,
because testing for blood is an important component of the test. Furthermore, the lesion in
question may have acquired a gene mutation not assessed by the mtSDNA test, which means
our assumption of conditional independence may be less likely to hold for the mtSDNA test
compared to gFOBT and FIT. As a result, we may have overestimated the benefit of stool tests
in general and of mtSDNA testing in particular, and its threshold reimbursement rate may be
even lower than estimated here.
Finally, because test-specific data on longitudinal screening patterns are lacking, our base-
case analysis assumes 100% adherence with screening, follow-up and surveillance procedures.
Uptake of screening among the Medicare population is considerably less than 100% [38], as is
adherence with repeat screening [51], follow-up [52] and surveillance [53]. Meanwhile, over-
use of resources is also common [54], and a positive stool test is sometimes followed by
another stool test instead of by the prescribed follow-up colonoscopy [55]. Although we did
include a sensitivity analysis with lower uptake, we assumed that individuals were either fully
adherent or fully non-adherent with screening. The impact of less-than-perfect adherence
among those who take up screening will vary according to the interval of testing and the char-
acteristics of the test. While stool-based testing may have higher initial acceptance rates,[56–
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59] patients’ willingness to comply with annual stool-based testing over longer periods of time
is uncertain,[60–62] and no data is available on adherence with triennial mtSDNA testing.
In summary, our analysis shows that compared with no screening, triennial mtSDNA test-
ing reduces CRC incidence and mortality. However, with perfect adherence, it is less effective
than other CRC screening options available to Medicare beneficiaries. At its current reim-
bursement rate, triennial mtSDNA testing also has higher costs than all other strategies, mak-
ing it an inefficient screening option. It could be efficient and potentially cost effective if
mtSDNA testing would increase adherence with CRC screening to nearly 100%. Triennial (or
more frequent) mtSDNA testing could also be potentially cost effective if the reimbursement
rate were substantially lower, i.e. similar to that of other stool-based tests.
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